Britain To Test Merck - Ridgeback Biotherapeutics' COVID-19 Antiviral Pill In Hospitalized Patients

Vandana Singh

Mon, Jan 24, 2022, 12:45 PM1 min read

In this article:

British scientists will start testing Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics' COVID-19 antiviral pill molnupiravir as a possible treatment for patients hospitalized with COVID-19, reported Reuters.

The pill is approved in Britain for use in people with mild to moderate COVID-19. Still, it is unknown whether it would work in patients hospitalized with severe illness, researchers of the RECOVERY trial said.
The study will compare 800 mg doses of molnupiravir, given twice daily for five days, with standard care for adult patients in hospitals because of COVID-19.
Related: Reddy's To Launch Generic Version Of Merck's COVID-19 Drug At Reddy's To Launch Generic Version Of Merck's COVID-19 Drug At $0.50/Pill: Reuters.50/Pill: Reuters.
"Adding molnupiravir (to the study) will allow us to study this drug on its own, but also in combination with other COVID-19 treatments," said Peter Horby, joint chief investigator of the trial and Oxford University professor.
Related: UK Calls For Additional Doses Of COVID-19 Antivirals From Merck, Pfizer.
Price Action: MRK shares are down 3.14% at $77.47 during the market session on the last check Monday.

See more from Benzinga

Here's Exactly When Social Security Recipients Can Expect Benefit Cuts, According to the Latest Trustees Report
Social Security payments may be subject to cuts. Here's what the timing looks like.
Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor added to these three existing positions on Tuesday.
Motley Fool
How Much Cash Can A $300,000 Annuity Generate For Me Each Month?
Imagine having a reliable source of income you can count on throughout your retirement. That’s the promise of an annuity. These insurance products have been designed to turn your savings into a steady stream of monthly payments. They guarantee peace of mind and financial security in your golden years. Don't Miss: Are you rich? Here’s what Americans think you need to be considered wealthy. Can you guess how many Americans successfully retire with $1,000,000 saved? The percentage may shock you. An
Benzinga
Can I Use My RMDs to Transfer Money Into My Roth IRA?
If you're taking a required minimum distribution from an IRA, 401(k) or other tax-deferred account and don't need the money to cover living expenses, where should you stash that unneeded cash? Investors now need to start taking RMDs at age 73 or, if they were born after 1960, at age 75. Depending on the balances of […] The post Can I Use My RMDs to Transfer Money Into My Roth IRA? appeared first on SmartReads by SmartAsset.
SmartAsset
Can You Guess What Percentage Of A High-Net-Worth Individual's Portfolio Is Typically Held In Retirement Accounts?
High net worth individuals (HNWIs) are those who have at least $1 million in easily convertible assets like cash, stocks, and bonds. They often manage significant wealth across diverse portfolios. As per Empower’s financial dashboard, retirement accounts such as 401(k) plans and IRAs comprise 55% of total wealth for many HNWIs. This is a stark contrast to the median household. Pew Research Center reports that these accounts typically represent only 27% of the net worth of households where at lea
Benzinga
3 Ridiculously Undervalued Stocks to Buy Hand Over Fist Right Now in May
Investing in cheap stocks brings unique risks because there is usually a reason the companies are undervalued.
Motley Fool
Andreessen Horowitz partner says Google is an ‘amazing example’ of employing people in ‘BS jobs’: ‘Half the white-collar staff probably does no real work’
“Those people aren’t just being useless (and being coddled to think useless jobs actually matter—they don’t), but they are also taking money away from the rest of the workforce’s retirement programs.”
Fortune
Why Coca-Cola Consolidated Stock Skyrocketed Over $1,000 Per Share Today
You won't believe the amount of money that the bottler intends to return to shareholders.
Motley Fool
Second Death - Pfizer Reports Young Boy's Death After One Year Of Gene Therapy Treatment In Muscle Wasting Disorder Trial
A young patient died due to cardiac arrest after receiving Pfizer Inc’s (NYSE:PFE) experimental gene therapy in a mid-stage trial for Duchenne muscular dystrophy (DMD), the company told in a letter to Parent Project Muscular Dystrophy. The boy was enrolled in Phase 2 DAYLIGHT study studying the treatment in boys at least two years old and under four years old. The patient received the investigational gene therapy, fordadistrogene movaparvovec (PF-06939926), in early 2023. Citing Pfizer, Reuters
Benzinga
Morgan Stanley Predicts up to 110% Rally for These 2 ‘Strong Buy’ Stocks
Uncertainty is the word of the day, in reference to the near-term economic future. Sentiment will hinge on the inflation numbers due out next week. March’s figure rose to 3.5%, and April’s job numbers showed a marked slowing in the labor market; that combination has stoked fears of stagflation. But – corporate earnings from Q1 are beating expectations, and the stock market has taken a turn for the better with the S&P 500 closing just below 5,200 yesterday. Economic strategists are still optimist
TipRanks

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Britain To Test Merck - Ridgeback Biotherapeutics' COVID-19 Antiviral Pill In Hospitalized Patients

Recommended Stories

Here's Exactly When Social Security Recipients Can Expect Benefit Cuts, According to the Latest Trustees Report

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

How Much Cash Can A $300,000 Annuity Generate For Me Each Month?

Can I Use My RMDs to Transfer Money Into My Roth IRA?

Can You Guess What Percentage Of A High-Net-Worth Individual's Portfolio Is Typically Held In Retirement Accounts?

3 Ridiculously Undervalued Stocks to Buy Hand Over Fist Right Now in May

Andreessen Horowitz partner says Google is an ‘amazing example’ of employing people in ‘BS jobs’: ‘Half the white-collar staff probably does no real work’

Why Coca-Cola Consolidated Stock Skyrocketed Over $1,000 Per Share Today

Second Death - Pfizer Reports Young Boy's Death After One Year Of Gene Therapy Treatment In Muscle Wasting Disorder Trial

Morgan Stanley Predicts up to 110% Rally for These 2 ‘Strong Buy’ Stocks